Paper Details

  1. Home
  2. Paper Details

Fruquintinib: First Global Approval.

Author: ShirleyMatt

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Fruquintinib, a VEGFR inhibitor, was approved for metastatic colorectal cancer in China. It has shown promise in treating other cancers and is in ongoing clinical development. This article outlines the development of this new drug for cancer treatment.
Paper Details　
Original Abstract of the Article :
Fruquintinib (Elunate<sup>&#174;</sup>) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours. In September 2018, fruquintinib received its first global approval,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40265-018-0998-z

データ提供：米国国立医学図書館（NLM）

Fruquintinib: A New Weapon in the Fight Against Cancer

Metastatic colorectal cancer (CRC) is a challenging and often aggressive disease. It's like a desert sandstorm, spreading quickly and threatening the body's health. This study focuses on fruquintinib, a new oral drug that has been approved for the treatment of metastatic CRC in patients who have failed other treatments. The researchers highlight the drug's mechanism of action, targeting specific receptors involved in tumor growth.

Fruquintinib: Finding a New Oasis in the Desert of Cancer

The study emphasizes the importance of fruquintinib as a new treatment option for metastatic CRC. It's like discovering a hidden oasis in the desert of cancer—offering a chance to slow down the disease's progression and improve quality of life.

Hope for Patients with Metastatic CRC: A Beacon of Light in the Desert

This study provides valuable information for patients with metastatic CRC, highlighting the potential of fruquintinib to improve treatment outcomes. It's like finding a beacon of light in the desert—offering hope and a renewed sense of optimism for patients who have been facing challenging circumstances.

Dr. Camel's Conclusion

This study is a testament to the ongoing progress in cancer research, offering a glimmer of hope for patients with metastatic colorectal cancer. It's like finding a new path through the desert—a path that leads towards better treatment options and a brighter future.
Date :
  1. Date Completed 2019-07-30
  2. Date Revised 2022-07-01
Further Info :

Pubmed ID

30357594

DOI: Digital Object Identifier

10.1007/s40265-018-0998-z

Related Literature

Article Analysis
・Effects of fruquintinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.